Practical application of duloxetine in the treatment of depression and anxiety. Frequently asked questions and doubts Review article
Article Sidebar
Published:
Jun 30, 2018
Keywords:
duloxetine, depression, generalized anxiety disorder, pain, SNRI
Main Article Content
Abstract
In recent years, a number of articles comparing duloxetine with other antidepressants have been published. Increasing experience with the use of duloxetine in different populations allows to draw conclusions and to compare duloxetine with other antidepressants, as well as to identify populations of patients who may in particular benefit from the treatment with duloxetine. The article summarizes the current state of knowledge on the practical use of duloxetine in the treatment of depression and anxiety, referring to the most frequently asked questions and doubts.
Article Details
How to Cite
Antosik-Wójcińska, A. (2018). Practical application of duloxetine in the treatment of depression and anxiety. Frequently asked questions and doubts. Medycyna Faktow (J EBM), 11(2(39), 112-117. https://doi.org/10.24292/01.MF.0218.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Eckert L., Lancon C.: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006; 6: 30.
2. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
3. Papakostas G.I., Thase M.E., Fava M. et al.: Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol. Psychiatry 2007; 62: 1217-1227.
4. Arnold L.M., Lu Y., Crofford L.J. et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
5. Arnold L.M., Rosen A., Pritchett Y.L. et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
6. Perahia D.G., Quail D., Desaiah D. et al.: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J. Psychiatr. Res. 2009a; 43: 512-518.
7. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
8. Romera I., Pérez V., Menchón J.M. et al.: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J. Affect. Disord. 2012; 143: 47-55.
9. Papakostas G.I., Fava M., Thase M.E. et al.: Treatment of SSRI-Resistant Depression: A Meta-analysis Comparing Within-Versus Across-Class Switches. Biol. Psychiatry 2008; 63: 699-674.
10. Karp J.F., Whyte E.M., Lenze E.J. et al.: Rescue Pharmacotherapy with Duloxetine for SSRI Nonresponders in Late Life Depression: Outcome and Tolerability. J. Clin. Psychiatry 2008; 69: 457-463.
11. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006b; 188: 346-353.
12. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
13. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13: 227-235.
14. Derby M.A., Zhang L., Chappell J.C. et al.: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J. Cardiovasc. Pharmacol. 2007; 49: 384-393.
15. Ball S.G., Desaiah D., Zhang Q. et al.: Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context 2013a; 2013: 212245.
16. Ball S., De Berardis D., Serroni N. et al.: The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr. Dis. Treat 2008; 4: 929-935.
17. Hartford J., Kornstein S., Liebowitz M. et al.: Duloxetine as an SNRI treat-ment for generalized anxiety disorder: results from a placebo and active- controlled trial. Int. Clin. Psychopharmacol. 2007; 22: 167-174.
18. Nierenberg A.A., Greist J.H., Mallinckrodt C.H. et al.: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin. 2007; 23: 401-416.
19. Shelton R.C., Prakash A., Mallinckrodt C.H. et al.: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int. J. Clin. Pract. 2007; 61: 1337-1348.
2. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
3. Papakostas G.I., Thase M.E., Fava M. et al.: Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol. Psychiatry 2007; 62: 1217-1227.
4. Arnold L.M., Lu Y., Crofford L.J. et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
5. Arnold L.M., Rosen A., Pritchett Y.L. et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
6. Perahia D.G., Quail D., Desaiah D. et al.: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J. Psychiatr. Res. 2009a; 43: 512-518.
7. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
8. Romera I., Pérez V., Menchón J.M. et al.: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J. Affect. Disord. 2012; 143: 47-55.
9. Papakostas G.I., Fava M., Thase M.E. et al.: Treatment of SSRI-Resistant Depression: A Meta-analysis Comparing Within-Versus Across-Class Switches. Biol. Psychiatry 2008; 63: 699-674.
10. Karp J.F., Whyte E.M., Lenze E.J. et al.: Rescue Pharmacotherapy with Duloxetine for SSRI Nonresponders in Late Life Depression: Outcome and Tolerability. J. Clin. Psychiatry 2008; 69: 457-463.
11. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006b; 188: 346-353.
12. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
13. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13: 227-235.
14. Derby M.A., Zhang L., Chappell J.C. et al.: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J. Cardiovasc. Pharmacol. 2007; 49: 384-393.
15. Ball S.G., Desaiah D., Zhang Q. et al.: Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context 2013a; 2013: 212245.
16. Ball S., De Berardis D., Serroni N. et al.: The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr. Dis. Treat 2008; 4: 929-935.
17. Hartford J., Kornstein S., Liebowitz M. et al.: Duloxetine as an SNRI treat-ment for generalized anxiety disorder: results from a placebo and active- controlled trial. Int. Clin. Psychopharmacol. 2007; 22: 167-174.
18. Nierenberg A.A., Greist J.H., Mallinckrodt C.H. et al.: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr. Med. Res. Opin. 2007; 23: 401-416.
19. Shelton R.C., Prakash A., Mallinckrodt C.H. et al.: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int. J. Clin. Pract. 2007; 61: 1337-1348.